The drugs at the center of the findings, known as antiresorptives, are a cornerstone of modern treatment for bone metastases. Breast cancer that has spread to the skeleton disrupts the normal balance of bone remodeling, tipping it toward excessive breakdown by cells called osteoclasts. This process causes pain, fractures, spinal cord compression and dangerously high calcium levels. Antiresorptive drugs work by suppressing osteoclast activity. Bisphosphonates, such as zoledronic acid, bind to bone mineral and poison the resorption machinery of osteoclasts, while denosumab, a monoclonal antibody, blocks RANKL, the signaling molecule that osteoclasts need to form, function and survive. By dampening bone turnover, these agents reduce skeletal complications and improve quality of life for patients with metastatic disease.

Yet the same mechanism that protects the skeleton carries a paradoxical risk in the jaw. Osteonecrosis of the jaw associated with these medications, abbreviated MRONJ, typically appears as exposed bone in the mouth that fails to heal for more than eight weeks, in patients with no history of radiation therapy to the head or neck. The jawbone is subject to constant mechanical stress from chewing and is frequently challenged by dental infections and procedures. When bone remodeling is profoundly suppressed, the normal repair of tiny injuries in the jaw may be impaired, and dead bone can persist as an open, infection-prone wound. The condition can cause pain, swelling, loose teeth and recurrent infections, and it is notoriously difficult to treat once established.

The Oulu research team designed their study as a retrospective nationwide registry analysis, combining data from the Finnish Institute for Health and Welfare and the Social Insurance Institution of Finland. This approach gave them access to a complete, population-based dataset rather than the selected patient groups seen at single hospitals. The cohort consisted of 652 breast cancer patients with bone metastases who received antiresorptive treatment between 2013 and 2015, and the researchers followed the patients until the end of 2020. That multi-year window matters, because osteonecrosis of the jaw can develop slowly over an extended period, and studies with shorter observation times may substantially underestimate how often it occurs.

The headline figures, 12.6 percent for denosumab alone and 15.3 percent for patients who switched from bisphosphonates to denosumab, are notably higher than many earlier estimates, which often ranged from a few percent in pooled analyses. The Finnish team attributes part of this difference to their long follow-up and their ability to capture diagnoses across the entire national healthcare system. Because the dataset covered all of Finland, the researchers could assess the incidence of the condition and the factors associated with it specifically among Finnish patients with breast cancer that had spread to the bones, something that had never been done before in the country.

Beyond the overall incidence, the study uncovered a telling pattern in the dental records. Dental procedures related to oral infections were associated with the development of osteonecrosis of the jaw. Tooth extraction and root canal treatment, in particular, were linked to a higher risk of the condition. Tooth extraction has long been recognized in the international literature as the most common triggering event for MRONJ, because it creates an open wound in bone whose healing capacity has been chemically dampened. The association with root canal treatment is more novel, but the researchers urge caution in interpreting it: the number of patients in the cohort who underwent root canal treatment was small, and the finding does not establish that the procedure itself causes osteonecrosis of the jaw. It may instead serve as a marker of underlying oral infection or inflammation.

Miika Kujanpää, a doctoral researcher at the University of Oulu, emphasized that the results should not alarm patients into abandoning their cancer treatment. The findings alone do not warrant changing or discontinuing antiresorptive therapy, he noted, and the benefits and potential risks must be assessed on an individual basis. Nor, he stressed, should necessary dental treatment be withheld because of the associations observed. What the results do highlight, according to Kujanpää, is the importance of identifying and adequately treating potential sources of oral infection before starting antiresorptive therapy, and of monitoring oral health continuously throughout the course of treatment. Achieving that, he said, requires close collaboration between oncology and oral healthcare professionals, two specialties that historically have not always coordinated closely.

This preventive message carries real clinical weight. If active infections and non-healing dental problems are resolved before a patient begins denosumab or bisphosphonates, the jaw enters treatment in the best possible condition, with no open wounds to seed necrosis. Once therapy has started, invasive dental work becomes more hazardous, because the suppressed bone turnover persists for months or even years after each dose, particularly with denosumab’s long-acting antibody mechanism. Many international guidelines already recommend a dental examination before initiating antiresorptive therapy, but adherence varies widely, and the Finnish data provide fresh, population-based evidence for why that recommendation matters in everyday oncology practice.

The researchers are careful to frame their study as a beginning rather than an endpoint. They call for further research into how drug dosage, treatment duration and cumulative exposure are associated with osteonecrosis of the jaw, questions that registry data alone cannot fully resolve. More precise information is also needed on the timing of oral infections, dental procedures and the onset of the condition, so that the effects of different contributing factors can be disentangled. And they underline the necessity of sufficiently long follow-up in future studies, since the condition can emerge over an extended period and shorter observation windows risk understating its true incidence.

Perhaps the most consequential question the study raises is also the most practical: how much planned, preventive oral healthcare can actually reduce the risk of osteonecrosis of the jaw? If a structured program of dental screening, infection control and timely treatment before and during antiresorptive therapy can meaningfully lower the incidence observed in Finland, the payoff for patients with metastatic breast cancer could be substantial, sparing them a painful and disabling complication without compromising the bone protection they need. The study was supported by research grants from the Finnish Dental Society Apollonia, and its publication in Clinical Oral Investigations marks a step toward evidence-based, jointly managed care at the intersection of cancer medicine and dentistry. For the hundreds of thousands of women worldwide living with breast cancer that has reached their bones, the message from Finland is clear: the teeth and jaws deserve a place on the treatment plan.

Subject of Research: Incidence and risk factors of medication-related osteonecrosis of the jaw in breast cancer patients with bone metastases receiving antiresorptive treatment

Article Title: Jawbone necrosis in advanced breast cancer: Finnish study highlights the importance of oral health

Article References: Jawbone necrosis in advanced breast cancer: Finnish study highlights the importance of oral health. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: osteonecrosis of the jaw, breast cancer, bone metastases, denosumab, bisphosphonates, antiresorptive drugs, oral health, tooth extraction, registry study, Finland, University of Oulu, Clinical Oral Investigations

The clinical stakes are considerable. MRONJ is defined clinically as exposed bone, or bone that can be probed through a fistula, in the maxillofacial region persisting for more than eight weeks in patients without prior radiation therapy or metastatic disease. Although incidence among osteoporosis patients on antiresorptives is typically below 0.2 percent, it rises to several percent or more among cancer patients receiving high-dose intravenous bisphosphonates. The consequences include chronic bone exposure, pain and impaired chewing, and the fear of the condition often forces clinicians to pause antiresorptive therapy around dental procedures, potentially undermining treatment of the underlying bone disease. Despite decades of investigation, no circulating biomarker has achieved reliable clinical adoption for identifying who is at risk.

Previous candidate markers have repeatedly disappointed. C-terminal telopeptide of type I collagen, tartrate-resistant acid phosphatase 5b, dickkopf-related protein 1, and the RANKL-to-osteoprotegerin ratio were all proposed over the years, but meta-analyses and guideline committees have largely rejected them, citing small, heterogeneous, single-centre studies and a hypothesis-driven focus on a narrow set of bone-turnover proteins. The Korean team, led by researchers at Seoul National University and Ewha Womans University, took a deliberately different route: an unbiased, high-resolution survey of the entire serum proteome, followed by validation in separate cohorts and population-scale data.

In the discovery phase, the researchers applied tandem mass tag-based quantitative proteomics to serum from 25 MRONJ patients and 16 medication-exposed controls, depleting the fourteen most abundant serum proteins to reveal the deeper proteome. The workflow quantified 1,481 proteins with high technical reproducibility, with median coefficients of variation between internal standard channels of roughly four percent. Among all of these, one protein stood out: dopamine β-hydroxylase, or DBH, was significantly less abundant in the MRONJ group, with an adjusted P value of 0.037 after Benjamini–Hochberg correction for multiple testing.

DBH is the enzyme that converts dopamine into norepinephrine inside sympathetic neurons and adrenal chromaffin cells, and it is co-released with norepinephrine during sympathetic activation. Because it circulates more stably than norepinephrine itself, it has long been proposed as a surrogate window onto sympathetic tone, though earlier small studies produced inconsistent results. To confirm the proteomic signal, the team measured DBH by enzyme-linked immunosorbent assay and found excellent agreement with the mass spectrometry data, with a Pearson correlation coefficient of 0.962. Median serum DBH in MRONJ patients was 915.1 picograms per millilitre, compared with 1,317 picograms per millilitre in controls, a difference that was highly statistically significant.

The association survived rigorous statistical scrutiny. In multivariable logistic regression adjusted for age and sex, each one-standard-deviation decrease in DBH was associated with nearly twelve-fold higher odds of MRONJ in the discovery cohort, with a receiver operating characteristic area under the curve of 0.848 and an optimal cut-off of 1,082 picograms per millilitre yielding 84 percent sensitivity and 81.3 percent specificity. Crucially, an independent validation cohort of 55 additional participants reproduced the direction of the effect, with lower DBH again significantly associated with MRONJ after adjustment. Sensitivity analyses excluding cancer patients, anti-angiogenic drug users, beta-blocker users, and users of any sympathetically active medication all preserved the association, arguing against confounding by concurrent drugs or comorbidities.

Population-scale data provided a third, independent line of evidence. Mining plasma proteomic measurements from 44,740 UK Biobank participants of white British ancestry, the researchers narrowed the analysis to 2,270 people with osteoporosis or bisphosphonate exposure, identifying 10 MRONJ cases and 2,224 controls. Using Firth’s penalized likelihood logistic regression to handle the rare outcome, they found that each standard-deviation decrease in plasma DBH was associated with 1.57-fold higher odds of MRONJ after adjusting for age, sex, body mass index, bisphosphonate use and genetic ancestry. The prevalence of MRONJ in this subset, 0.45 percent, matched expectations for antiresorptive-exposed populations, lending credibility to the case definitions.

To establish that circulating DBH genuinely tracks sympathetic activity, the team turned to blood pressure, a classic downstream readout of sympathetic tone. Across 34,948 UK Biobank participants, plasma DBH was positively associated with both systolic and diastolic blood pressure after adjustment for age, sex, body mass index, smoking, drinking and genetic principal components. Spline and quantile regression analyses showed the relationship strengthening at higher blood pressures, and participants in the top 30 percent of DBH levels had significantly elevated odds of hypertension. These data rehabilitate DBH as a population-level marker of sympathetic tone and suggest that the low DBH seen in MRONJ patients reflects genuinely altered sympathetic regulation rather than a mere biochemical curiosity.

The mechanistic twist came from the laboratory. In a mouse model in which repeated zoledronic acid administration combined with maxillary molar extraction reliably produces jawbone necrosis, the researchers added propranolol, a non-selective beta-adrenergic blocker, to pharmacologically suppress sympathetic signalling. Propranolol did not change bone structure beyond what zoledronic acid achieved, but it dramatically worsened the disease itself: histology revealed significantly larger necrotic bone areas in the combination group than with zoledronic acid alone. Tartrate-resistant acid phosphatase staining showed that propranolol further reduced the number of giant, dysfunctional osteoclasts that zoledronic acid induces, particularly at non-extraction sites, indicating an additive suppression of bone resorption on top of an already profound antiresorptive state.

Co-culture experiments fleshed out the cellular logic. When primary mouse osteoblasts were stimulated with the beta-adrenergic agonist isoproterenol, the ratio of RANKL to osteoprotegerin, the key osteoblast-derived signals that drive osteoclast differentiation, rose sharply, and propranolol abolished this effect. Zoledronic acid left the RANKL-to-osteoprotegerin ratio untouched, yet in functional osteoblast–osteoclast co-cultures the two drugs acted through distinct pathways to inhibit osteoclast formation additively. Since excessive suppression of bone resorption is widely regarded as the central mechanism of MRONJ, the authors propose that reduced sympathetic signalling, as reflected by low circulating DBH, may push osteoclast activity below the threshold needed for jawbone maintenance, particularly in the high-turnover alveolar bone of the jaw. The team is careful to note limitations: DBH was measured after disease onset, so prospective studies are needed to confirm predictive value, and the UK Biobank case definitions carry some classification uncertainty. Even so, the convergence of clinical proteomics, population genetics-scale validation and animal experimentation makes circulating DBH the most credible candidate biomarker for MRONJ risk stratification to date, and opens an entirely new chapter in the neuro-skeletal biology of the jaw.

Subject of Research: Circulating dopamine β-hydroxylase as a biomarker and sympathetic dysregulation mechanism in medication-related osteonecrosis of the jaw

Article Title: Decreased circulating dopamine β-hydroxylase is associated with medication-related osteonecrosis of the jaw and implicates sympathetic dysregulation

Article References: Decreased circulating dopamine β-hydroxylase is associated with medication-related osteonecrosis of the jaw and implicates sympathetic dysregulation. (n.d.). https://doi.org/10.1038/s12276-026-01868-z

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01868-z

Keywords: medication-related osteonecrosis of the jaw, dopamine beta-hydroxylase, sympathetic nervous system, bisphosphonates, antiresorptive therapy, serum proteomics, UK Biobank, osteoclasts, biomarker, propranolol, bone remodeling, norepinephrine

MINS is one of the most consequential and underappreciated phenomena in modern perioperative medicine. It is defined as a rise in cardiac troponin, a protein released when heart muscle cells are damaged, above the 99th percentile of the normal reference range in the days following an operation that does not involve the heart itself. Crucially, most patients with MINS experience no chest pain, no shortness of breath, and no electrocardiographic changes, because the injury is often a diffuse supply-demand mismatch rather than a classic clot-blocking heart attack. The landmark VISION studies, which screened tens of thousands of surgical patients with high-sensitivity troponin assays, demonstrated that postoperative troponin elevation independently predicts 30-day mortality, even when the injury is asymptomatic. This is why the American Heart Association and the European Society of Cardiology have issued dedicated guidance urging clinicians to consider troponin surveillance in high-risk noncardiac surgery populations.

The new study, led by Yiwen Liu, Yongping Ma, and Yuxing Guo across institutions including Peking University School and Hospital of Stomatology, Peking University International Hospital, and Baoding Second Hospital, focused on a patient group that sits at the intersection of oncology, dentistry, and cardiology. The researchers analyzed 65 patients with cancer-related MRONJ who underwent surgical treatment between October 2024 and May 2025. Blood levels of high-sensitivity cardiac troponin I, one of the most sensitive biochemical detectors of heart muscle damage available, were measured before surgery and again within 72 hours afterward. MINS was diagnosed according to established international criteria, and the clinical characteristics of patients who developed the condition were systematically compared with those who did not.

The headline finding was stark in its simplicity: 7 of the 65 patients, or 10.8 percent, developed MINS. That figure may appear modest, but in a population already weakened by cancer and its therapies, it represents a meaningful signal. Postoperative myocardial injury is not a benign laboratory curiosity; it is a predictor of major adverse cardiac events and death, and identifying who is vulnerable before the scalpel touches tissue is one of the central goals of perioperative risk stratification. What makes this study particularly interesting is not just the incidence but the pattern of risk factors that emerged when the investigators compared the two groups.

Patients who developed MINS had a significantly lower body mass index than those who did not, a difference that reached statistical significance at P = 0.003. They also had a higher prevalence of preoperative myocardial injury, meaning their troponin levels were already elevated before the operation began, a finding significant at P = 0.005. In addition, the MINS group showed lower preoperative serum albumin levels, a marker of protein nutrition and overall nutritional reserve, and significantly more severe anemia, defined using World Health Organization hemoglobin cutoffs. Spearman correlation analysis quantified these relationships: MINS showed a moderate positive correlation with preoperative myocardial injury, with a correlation coefficient of 0.435, and a negative correlation with BMI, at minus 0.366. The correlations among BMI, serum albumin, and anemia severity themselves were also significant, painting a picture of interconnected vulnerability rather than isolated risk factors.

The physiological logic behind these associations is compelling. A patient with low BMI and hypoalbuminemia is often malnourished or cachectic, with depleted cardiac reserve, reduced antioxidant defenses, and impaired capacity to tolerate the inflammatory surge that accompanies any surgical intervention. Anemia compounds the problem by reducing the oxygen-carrying capacity of the blood, forcing the heart to beat faster and harder to deliver the same amount of oxygen to tissues, including the myocardium itself. Under general anesthesia, blood pressure fluctuates, oxygen demand shifts, and the balance between myocardial oxygen supply and demand becomes precarious. In a heart already operating near its limits, that balance can tip, producing the subclinical myocyte damage that registers as a troponin rise. Preoperative myocardial injury, meanwhile, marks a myocardium that is already stressed, making it the strongest correlated factor in the study.

The context of the operation matters as much as the patient. MRONJ surgery is performed on the jaw, far from the heart, yet it involves infection, inflammation, and often prolonged procedures in patients taking multiple medications. Cancer itself is now recognized as an independent risk factor for perioperative arterial ischemic events, and the emerging discipline of cardio-oncology, codified in the 2022 European Society of Cardiology guidelines, emphasizes that cancer therapies, shared risk factors such as diabetes and smoking, and the systemic inflammatory state of malignancy all conspire to elevate cardiovascular risk. Patients with MRONJ are typically receiving or have received long courses of antiresorptive therapy, and many have breast cancer, prostate cancer, or multiple myeloma, diseases whose treatments can themselves affect the heart. The study’s authors positioned their work within this cardio-oncology framework, noting that non-cancer mortality is a major contributor to overall mortality among people diagnosed with cancer.

What distinguishes this investigation is its emphasis on nutrition as a modifiable axis of perioperative risk. Serum albumin has long served as a workhorse biomarker in surgical outcome prediction, appearing in composite indices such as the prognostic nutritional index, and low values consistently correlate with worse postoperative outcomes across surgical specialties. By demonstrating that BMI, albumin, and anemia cluster together and jointly associate with MINS, the study suggests that nutritional assessment, a step often relegated to a brief checklist item, could become a genuine gatekeeping tool before jaw surgery in cancer patients. If malnourished, anemic patients can be identified weeks before surgery, clinicians have a window to optimize hemoglobin through iron supplementation or transfusion where appropriate, improve protein intake, and thereby potentially shift the supply-demand equation in the patient’s favor before the operative stress arrives.

The authors are appropriately cautious about the strength of their conclusions. This was an exploratory, retrospective study with a small sample size, and only seven patients experienced the outcome, a number that limits the statistical power of multivariable modeling; the field’s own methodological conventions, such as the events-per-variable rule from logistic regression research, caution against overfitting models built on so few events. The study followed STROBE reporting guidelines and was approved by ethics committees at all three participating institutions, but the authors explicitly state that the observed associations require confirmation in larger, prospective studies before they can drive clinical practice. Retrospective designs also cannot exclude confounding by unmeasured variables, and the 72-hour troponin window, while consistent with standard definitions, captures only the early postoperative period.

Even with those caveats, the study adds a distinctive piece to the growing mosaic of perioperative cardiology. It suggests that a seemingly minor maxillofacial operation in a cancer patient is not cardiovascularly neutral, that the troponin assay can unmask silent heart injury in this population, and that the body’s nutritional state, measured through something as mundane as body weight, blood protein, and hemoglobin, may determine whether the heart weathers the surgical storm. For clinicians managing MRONJ, the practical takeaway is a call to widen the preoperative lens: assess nutrition, check hemoglobin, and consider baseline troponin testing so that the patients most likely to sustain silent myocardial injury can be flagged, monitored, and supported. For the broader field, the finding reinforces a theme that has been building across perioperative medicine for a decade, namely that the heart’s fate after surgery is written partly in the blood, the body composition, and the biology of the patient long before the first incision is made.

Subject of Research: Myocardial injury after noncardiac surgery in oncology patients treated surgically for medication-related osteonecrosis of the jaw

Article Title: Myocardial injury in oncology patients undergoing noncardiac surgery for MRONJ: risk factors and nutritional associations

Article References: Liu, Y., Zhu, T., Zhou, B., Wang, P., Yang, Z., Yang, M., An, N., Liu, X., Wang, W., Chen, X., Zhang, Y., Ma, Y., & Guo, Y. (2026). Myocardial injury in oncology patients undergoing noncardiac surgery for MRONJ: risk factors and nutritional associations. Supportive Care in Cancer, 34(10), Article 1022. https://doi.org/10.1007/s00520-026-11259-9

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11259-9

Keywords: MRONJ, myocardial injury after noncardiac surgery, MINS, high-sensitivity troponin, cancer, perioperative risk, nutrition, anemia, hypoalbuminemia, body mass index, cardio-oncology, jaw surgery

The investigation was carried out by Fatma Kumbara and Filiz Eser of the Department of Physical Medicine and Rehabilitation at Ankara Bilkent City Hospital in Turkey. The researchers screened 2,153 clinical records of patients with osteoporosis who had been treated with antiresorptive agents, and 1,131 of those records met the inclusion criteria for the retrospective cohort study. Antiresorptive therapy is the backbone of modern osteoporosis management, encompassing drugs such as bisphosphonates and denosumab that suppress the bone-resorbing activity of osteoclasts, thereby reducing fracture risk in patients whose bones have become porous and fragile. The very mechanism that makes these drugs effective, however, also underlies the rare but serious jaw complication that the Turkish team set out to investigate.

MRONJ is defined by the American Association of Oral and Maxillofacial Surgeons as exposed bone, or bone that can be probed through an intraoral or extraoral fistula, in the maxillofacial region that has persisted for more than eight weeks in a patient with no history of radiation therapy to the jaw and no obvious metastatic disease. The condition is uncommon, but it is clinically important because it can cause pain, infection, loosening of teeth and significant deterioration in quality of life, and because it is difficult to treat once established. In their study, Kumbara and Eser diagnosed and staged MRONJ according to the 2022 AAOMS criteria, ensuring that their case definitions aligned with the most current international consensus on the disease.

The headline finding of the study is a prevalence of 2.3 percent, with 26 of the 1,131 patients receiving a diagnosis of MRONJ during the observation window. While that figure may seem small, it represents a substantial burden when multiplied across the millions of osteoporotic patients worldwide who take antiresorptive medication, and it is considerably higher than the prevalence figures often quoted in early clinical trials of bisphosphonates for osteoporosis. Real-world cohorts such as this one capture the messy reality of clinical practice, including patients with poor oral health, long treatment durations and variable adherence to dental monitoring, and they therefore provide a more accurate picture of risk than the highly selected populations enrolled in pharmaceutical trials.

The statistical analysis at the heart of the paper involved both univariate and multivariate logistic regression, the standard technique for isolating the independent contribution of each candidate risk factor while controlling for all the others. The researchers collected demographic, clinical, treatment-related and oral-dental characteristics for every patient and tested whether factors such as age, sex, comorbidities, corticosteroid use, the type of antiresorptive drug used, the duration of therapy and dental history were associated with the development of MRONJ. When all variables were entered into the multivariable model, two emerged as significant. A longer cumulative duration of antiresorptive therapy was independently associated with MRONJ, with an odds ratio of 1.03 per unit increase in treatment time, a 95 percent confidence interval of 1.01 to 1.06 and a p value of 0.010. A history of tooth extraction carried a far larger effect, with an odds ratio of 9.74, a 95 percent confidence interval of 2.48 to 38.26 and a p value of 0.001, meaning patients who had undergone an extraction were nearly ten times more likely to develop the condition than those who had not.

The finding on treatment duration fits with a large body of mechanistic and epidemiological evidence. Bisphosphonates bind to hydroxyapatite crystals in bone and accumulate at sites of active remodeling, and because jawbone undergoes high mechanical loading and frequent remodeling, these drugs concentrate in the mandible and maxilla to a remarkable degree. Over years of therapy, the suppression of osteoclast-mediated bone turnover in the jaw impairs the ability of the bone to repair itself after trauma, whether from extraction, periodontal disease or denture irritation. Each additional month of cumulative exposure, the new data suggest, nudges the risk upward incrementally, and the dose-response relationship captured by the odds ratio of 1.03 provides quantitative support for the clinical practice of periodically reassessing the need for continued antiresorptive therapy in patients on long-term treatment.

The association with tooth extraction is even more striking and is consistent with a growing international literature. Extraction creates an open wound in bone that is simultaneously suppressed in its remodeling capacity, and the alveolar socket must rely on residual osteogenic activity to fill with new bone and re-cover itself with soft tissue. When that regenerative capacity is blunted, the socket fails to heal, mucosa breaks down and exposed necrotic bone becomes a portal for oral bacteria. Recent systematic reviews and meta-analyses, including a 2025 meta-analysis of osteonecrosis following extraction in osteoporotic patients, have reported elevated risks associated with invasive dental procedures, and position papers from Italy, Korea and the Asia-Pacific region issued between 2024 and 2026 all emphasize preventive dental assessment before or early in the course of antiresorptive therapy. The nearly tenfold increase in odds observed in the Turkish cohort underscores just how pivotal the extraction socket is as the initiating event for most cases of MRONJ.

Equally important is what the study did not find. Drug holidays, the practice of temporarily interrupting antiresorptive therapy around the time of invasive dental procedures, diabetes mellitus, corticosteroid use and immunosuppressive therapy were not independently associated with MRONJ in the multivariable model. This is a notable result because drug holidays are widely recommended in clinical guidance documents, yet evidence for their effectiveness has been inconsistent. A 2025 systematic review and network meta-analysis of different antiresorptive discontinuation regimens in patients undergoing dental procedures found heterogeneous results, and the new cohort adds to the skepticism by failing to detect a protective signal. The authors caution, however, that the retrospective design and sample size may limit the power to detect smaller effects, and the question of whether temporary discontinuation genuinely reduces risk remains open.

The severity distribution among the 26 affected patients offers a mildly reassuring note. The majority, 69.2 percent, had stage 1 disease, which by AAOMS criteria involves exposed bone without infection or symptoms, while 30.8 percent had progressed to stage 2, characterized by exposed bone with infection, pain, erythema or purulent drainage. No patients with stage 3 disease, which involves more extensive necrosis extending beyond the alveolar bone or complications such as pathologic fracture, extraoral fistula or involvement of the inferior border of the mandible, were reported in this cohort. Early-stage disease can often be managed conservatively with antimicrobial rinses, antibiotics and local measures, which reinforces the importance of early detection through regular dental surveillance in patients on antiresorptive therapy.

The clinical message from the study is ultimately a preventive one. The authors conclude that careful dental assessment and multidisciplinary planning of invasive dental procedures may help reduce MRONJ risk in high-risk patients, a recommendation that echoes the 2024 guidance from the Scottish Dental Clinical Effectiveness Programme and successive international consensus statements. In practical terms, this means that patients about to begin long-term antiresorptive therapy should undergo a thorough dental evaluation, with treatment of active periodontal disease, restoration of carious teeth and completion of any necessary extractions before the first dose is administered, when the bone still retains its full regenerative capacity. For patients already on therapy, especially those with years of cumulative exposure, dental procedures should be planned jointly between the treating physician, dentist and oral surgeon, with the least invasive options considered first and meticulous wound management employed when extractions are unavoidable.

The broader context is the tension at the heart of osteoporosis care. Antiresorptive drugs prevent debilitating hip and vertebral fractures, which carry substantial mortality and morbidity, and the absolute risk of MRONJ remains low enough that experts overwhelmingly agree patients should not forgo needed therapy out of fear of jaw necrosis. Indeed, a 2025 systematic review and taskforce consensus statement concluded that antiresorptive therapy should continue to be used to reduce fracture risk even in patients contemplating dental implants. What studies like this one contribute is precision: by identifying who is genuinely at elevated risk, namely those with long cumulative exposure and those facing tooth extraction, clinicians can target their preventive efforts and their monitoring to the patients who need them most, rather than imposing blanket restrictions that could leave vulnerable bones unprotected.

For the millions of older adults living with osteoporosis, the take-home message is not to stop their medication but to take their oral health as seriously as their bone health. Regular dental check-ups, prompt attention to loose teeth, gum infections or non-healing sores, and honest communication between dentist and physician about antiresorptive exposure can catch problems before they escalate. As this new cohort from Ankara demonstrates, the risk of MRONJ in osteoporosis is real but manageable, and the levers for reducing it, limiting unnecessary invasive dental trauma and re-evaluating the duration of therapy over time, are firmly in the hands of an informed and coordinated clinical team.